Wista Laboratories Ltd.

Scott Clunas

John Mervyn David Storey

Claude Michel Wischik

Charles Robert Harrington

Janet Elizabeth Rickard

David Horsley

James Peter Sinclair

Colin Marshall

Michael Simpson

Thomas Craven Baddeley

Karrar Ahmad Khan

Craig Williamson

Christopher Paul Larch

Ahtsham Ishaq

Barry Alan Wood

Yin Sze Loh

John Mervyn Storey

Steven John Kemp

Tobias Heinrich

Sarah Louise Nicoll

Helen Sarah Gibbard

Lynda Jane Storey

Tobias Kerst Heinrich

Michel Wischik Claude

Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Phenothiazine diaminium salts and their use

Described are a compound of formula (II) or (III):  The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.

3,6-disubstituted xanthylium salts

The present invention pertains generally to the field of chemical synthesis, and more particularly to methods of chemical synthesis which include the step of preparing a substituted 10H-phenothiazine-3,7-diamine compound of Formula (1) by a step of selective alkylation by reductive amination, in which the corresponding unsubstituted diamine of Formula (4) is reacted with aldehyde/ketone, under reductive amination conditions. The present invention also relates to such methods which incorporate additional subsequent and/or preceding steps, for example, to prepare compounds of Formulae (2) and (3) from compounds of Formula (1), and to prepare compounds of Formula (4) from, for example, compounds of Formulae (5), (6), (7), (8), and (9). Compounds of Formula (1), Formula (2), and Formula (3) are useful, for example, in the treatment of diseases of protein aggregation, such as Alzheimer's disease.

Methods of chemical synthesis of substituted 10H-phenothiazine-3,7-diamine compounds

The invention relates to compounds of general formula (I): wherein: each of Rand Ris independently selected from: &#x2014;H, Calkyl, Calkenyl, and halogenated Calkyl; each of Rand Ris independently selected from: &#x2014;H, Calkyl, Calkenyl, and halogenated Calkyl; each of R7NA and R7NB is independently selected from: &#x2014;H, Calkyl, Calkenyl, and halogenated Calkyl; and wherein: each of Rand Ris independently selected from: Calkyl, halogenated Calkyl, and Caryl; or Rand Rare linked to form a group selected from: Calkylene and Carylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts. 

Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF. 

Ligands for aggregated tau molecules

This invention pertains generally to processes, uses, methods and materials utilizing particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease. 

3,6-disubstituted xanthylium salts and use thereof in treatment of tauopathies

Growing community of inventors

Old Aberdeen, United Kingdom

Scott Clunas